Going up against these giants is no small challenge, but Viking is, so far, holding its own. And if it can play its cards ...

Structure Therapeutics has dropped over 55% as its GLP-1 pill targets obesity, yet analysts remain bullish with high price ...

The FDA has granted accelerated approval to Wegovy® (semaglutide) as the first treatment for MASH with moderate-to-advanced ...

Denmark’s Novo Nordisk scored a significant regulatory win for GLP-1 drug Wegovy (semaglutide), as the US Food and Drug ...

PLAINSBORO, NJ, USA I August 15, 2025 I Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a new indication for Wegovy® ...

Novo Nordisk has elevated Dr Gaurav Yadav as Cardiometabolic Medical Director for the Business Area Africa Medical & ...

The Food and Drug Administration (FDA) has further expanded the U.S. indications of Novo Nordisk’s (NVO) popular weight loss therapy Wegovy, allowing its use against metabolic dysfunction-associated ...

Wegovy® (semaglutide) injection 2.4 mg is now indicated to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver ...

Plainsboro: Novo Nordisk has received approval from the US Food and Drug Administration (FDA) for a new indication for Wegovy (semaglutide) injection 2.4 mg, making it the first and ...

Novo Nordisk A/S’s weight-loss drug Wegovy has received FDA approval to treat a serious form of liver disease, giving the ...

Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...

Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators to treat an increasingly common liver disease, MASH.